Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Novo-Nordisk-fda-Mim8

More Like This

PR Newswire associated0

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

PR Newswire associated0

Precision BioLogic Leads the Way in Hemophilia Testing

PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe